质子束治疗继发性胶质母细胞瘤(髓母细胞瘤术后放疗32年后):病例报告与文献回顾
一例9岁确诊髓母细胞瘤的男性患者,接受钴-60全中枢放疗(36 Gy/20次)及瘤床推量(总56 Gy),32年后于41岁出现左小脑半球占位,术后病理确诊为放射性诱导胶质母细胞瘤(RIGB)。鉴于既往放疗史及当前脑干剂量耐受性,选择质子束治疗(PBT)联合替莫唑胺(75 mg/m2),处方为大体肿瘤床60 Gy、临床靶区54 Gy,分30次照射,随访达完全缓解。
要点
- 儿童肿瘤幸存者发生第二原发肿瘤显著影响预后,RIGB为罕见类型,分子特征与原发性及复发性继发性胶质母细胞瘤不同。
- IDH与MGMT状态等分子标志物有助于鉴别有放疗史患者的原发性胶质母细胞瘤、复发性继发性胶质母细胞瘤与放射性诱导继发性胶质母细胞瘤。
- 手术切除仍是主要治疗选择,PBT因对正常组织保护更优且能给予高剂量照射,为术后首选治疗。
核心结论
- RIGB是一种罕见的第二原发肿瘤,需要策略性分子分型与个体化管理。
- 质子束治疗可在术后阶段提供有效的高剂量照射,是该类病例的首选治疗选择。
研究设计与样本
- 病例报告与文献回顾:1例男性患者9岁确诊髓母细胞瘤,接受钴-60全中枢放疗(36 Gy/20次)及瘤床推量(总56 Gy),32年后41岁时MRI发现左小脑半球占位。
主要发现
- 手术切除后病理确诊为放射性诱导胶质母细胞瘤(RIGB)。
- 采用质子束治疗联合替莫唑胺(75 mg/m2),计划大体肿瘤床60 Gy、临床靶区54 Gy,分30次照射。
- 患者定期随访并达到完全缓解。
关键数值与推荐
- 质子束治疗剂量:大体肿瘤床60 Gy、临床靶区54 Gy,分30次照射;替莫唑胺剂量75 mg/m2。
- 既往放疗剂量:钴-60全中枢放疗36 Gy/20次,瘤床推量总56 Gy。
- 分子标志物IDH与MGMT状态有助于鉴别原发性胶质母细胞瘤、复发性继发性胶质母细胞瘤与放射性诱导继发性胶质母细胞瘤。
临床怎么用
- 手术切除仍是主要治疗选择。
- PBT因对正常组织保护更优且能给予高剂量照射,为术后首选治疗。
- 作者认为RIGB需策略性分子分型与个体化管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This report details the experience of a patient who developed a second primary glioblastoma (GB), offering insights into the treatment process and reviewing relevant literature. CASE PRESENTATION: A male patient, who was diagnosed with medulloblastoma at age 9, received treatment with cobalt-60 craniospinal irradiation (CSI) (36 Gy/20 fractions) and a tumor bed boost (total of 56 Gy). After 32 years, at age 41, an MRI revealed a space-occupying mass in the left cerebellar hemisphere. Surgical resection was performed, and postoperative pathology confirmed a diagnosis of radiation-induced glioblastoma (RIGB). Given the history of irradiation and the current tolerability of brainstem doses, proton beam therapy (PBT) combined with Temozolomide (75 mg/m2) was chosen. The treatment plan included 60 Gy on the gross tumor bed and 54 Gy on the clinical target volume, delivered in 30 fractions. The patient underwent regular follow-up and achieved a complete response. CLINICAL DISCUSSION: For childhood cancer survivors, the development of a second primary tumor significantly impacts prognosis. RIGB is a rare form of secondary tumor with distinct molecular characteristics compared to primary GB and recurrent secondary GB. Molecular markers such as IDH and MGMT status can help differentiate between primary GB, recurrent secondary GB, and radiation-induced secondary GB in patients with a history of prior radiation therapy. Surgical resection remains a primary treatment option, while PBT is preferred for postoperative treatment due to its superior protection of normal tissues and the ability to deliver high-dose irradiation. CONCLUSION: RIGB is a rare second primary tumor that requires strategic molecular profiling and individualized management. Proton beam therapy provides effective high-dose irradiation in the postoperative phase and is the preferred treatment option for such cases.
引用
- Jiwei B, Abulimiti M, Yonglong J, et al. Proton beam therapy in a patient with secondary glioblastoma (32 years after postoperative irradiation of medulloblastoma): case report and literature review. Radiat Oncol. 2024. PMID: 39369243. doi:10.1186/s13014-024-02515-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。